Radiation Oncology Journal

The Korean Society for Radiation Oncology (대한방사선종양학회)
권호 표지
DOI QR코드

DOI QR Code

The location of locoregional recurrence in pathologic T3N0, non-irradiated lower rectal cancer

  • Kim, Mi Sun (Department of Radiation Oncology, Yonsei University College of Medicine) ;
  • Keum, Ki Chang (Department of Radiation Oncology, Yonsei University College of Medicine) ;
  • Rhee, Woo Joong (Department of Radiation Oncology, Yonsei University College of Medicine) ;
  • Kim, Hyunju (Department of Radiation Oncology, Yonsei University College of Medicine) ;
  • Kim, Minji (Department of Radiation Oncology, Yonsei University College of Medicine) ;
  • Choi, Seohee (Department of Radiation Oncology, Yonsei University College of Medicine) ;
  • Nam, Ki Chang (Department of Medical Engineering, Yonsei University College of Medicine) ;
  • Koom, Woong Sub (Department of Radiation Oncology, Yonsei University College of Medicine)
  • Received : 2013.04.12
  • Accepted : 2013.06.05
  • Published : 2013.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: To investigate the patterns of locoregional recurrence of pathologic T3N0 (pT3N0) lower rectal cancer omitting postoperative radiotherapy (RT) and explore the potential of modification of a RT field. Materials and Methods: From Jan 2003 to Nov 2011, 35 patients omitting preoperative or postoperative RT for pT3N0 lower rectal cancer were included. We defined the lower rectal cancer as the tumor with the inferior margin located below the virtual line-a convergent level between rectal wall and levator ani muscle. All patients had radiologic examinations for recurrence evaluation during the follow-up duration. Results: The median follow-up duration was 66.4 months (range, 1.4 to 126.1 months). Eight (22.9%) of the 35 patients had recurrence. Three (8.6%) was local recurrence (LR) only, 3 (8.6%) was distant metastasis (DM) only, and 2 (5.7%) was LR with DM. All LR were located at primary tumor sites. The overall survival rate, LR-free survival rate, and DM-free survival rate at 5 years was 79.8%, 83%, and 87%, respectively. All LR developed from tumors over 5 cm. However, there was no statistical significance (p = 0.065). There was no other risk factor for LR. Conclusion: Even though the patients included in this study had pathologically favorable pT3N0 rectal cancer, LR developed in 14.3% of patients. Most of the LR was located at primary tumor sites prior to surgery. Based on these findings, it might seem reasonable to consider postoperative RT with a smaller radiation field to the primary tumor site rather than the conventional whole pelvic irradiation.

Keywords

References

  1. Kapiteijn E, Marijnen CA, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001;345:638-46. https://doi.org/10.1056/NEJMoa010580
  2. Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004;351:1731-40. https://doi.org/10.1056/NEJMoa040694
  3. Hyams DM, Mamounas EP, Petrelli N, et al. A clinical trial to evaluate the worth of preoperative multimodality therapy in patients with operable carcinoma of the rectum: a progress report of National Surgical Breast and Bowel Project Protocol R-03. Dis Colon Rectum 1997;40:131-9. https://doi.org/10.1007/BF02054976
  4. Gunderson LL, Sargent DJ, Tepper JE, et al. Impact of T and N substage on survival and disease relapse in adjuvant rectal cancer: a pooled analysis. Int J Radiat Oncol Biol Phys 2002;54:386-96. https://doi.org/10.1016/S0360-3016(02)02945-0
  5. Schmoll HJ, Van Cutsem E, Stein A, et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer: a personalized approach to clinical decision making. Ann Oncol 2012;23:2479-516. https://doi.org/10.1093/annonc/mds236
  6. Peeters KC, van de Velde CJ, Leer JW, et al. Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients: a Dutch colorectal cancer group study. J Clin Oncol 2005;23:6199-206. https://doi.org/10.1200/JCO.2005.14.779
  7. Gunderson LL, Callister M, Marschke R, Young-Fadok T, Heppell J, Efron J. Stratification of rectal cancer stage for selection of postoperative chemoradiotherapy: current status. Gastrointest Cancer Res 2008;2:25-33.
  8. Gunderson LL, Sargent DJ, Tepper JE, et al. Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis. J Clin Oncol 2004;22:1785-96. https://doi.org/10.1200/JCO.2004.08.173
  9. Park IJ, Kim HC, Yu CS, Kim TW, Jang SJ, Kim JC. Effect of adjuvant radiotherapy on local recurrence in stage II rectal cancer. Ann Surg Oncol 2008;15:519-25. https://doi.org/10.1245/s10434-007-9643-x
  10. Frasson M, Garcia-Granero E, Roda D, et al. Preoperative chemoradiation may not always be needed for patients with T3 and T2N+ rectal cancer. Cancer 2011;117:3118-25. https://doi.org/10.1002/cncr.25866
  11. Dahlberg M, Glimelius B, Graf W, Pahlman L. Preoperative irradiation affects functional results after surgery for rectal cancer: results from a randomized study. Dis Colon Rectum 1998;41:543-9. https://doi.org/10.1007/BF02235256
  12. Marijnen CA, Kapiteijn E, van de Velde CJ, et al. Acute side effects and complications after short-term preoperative radiotherapy combined with total mesorectal excision in primary rectal cancer: report of a multicenter randomized trial. J Clin Oncol 2002;20:817-25. https://doi.org/10.1200/JCO.20.3.817
  13. Wang BL, Jiang W, Du SS, Xu JM, Zeng ZC. The therapeutic and adverse effects of modified radiation fields for patients with rectal cancer. Clin Colorectal Cancer 2012;11:255-62. https://doi.org/10.1016/j.clcc.2012.06.001
  14. Loos M, Quentmeier P, Schuster T, et al. Effect of preoperative radio(chemo)therapy on long-term functional outcome in rectal cancer patients: a systematic review and meta-analysis. Ann Surg Oncol 2013;20:1816-28. https://doi.org/10.1245/s10434-012-2827-z
  15. Nijkamp J, Kusters M, Beets-Tan RG, et al. Three-dimensional analysis of recurrence patterns in rectal cancer: the cranial border in hypofractionated preoperative radiotherapy can be lowered. Int J Radiat Oncol Biol Phys 2011;80:103-10. https://doi.org/10.1016/j.ijrobp.2010.01.046
  16. Syk E, Torkzad MR, Blomqvist L, Nilsson PJ, Glimelius B. Local recurrence in rectal cancer: anatomic localization and effect on radiation target. Int J Radiat Oncol Biol Phys 2008;72:658-64. https://doi.org/10.1016/j.ijrobp.2008.01.063
  17. Bosset JF, Calais G, Mineur L, et al. Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results-EORTC 22921. J Clin Oncol 2005;23:5620-7. https://doi.org/10.1200/JCO.2005.02.113

Cited by

  1. The Magnetic Resonance Imaging-Based Approach for Identification of High-Risk Patients With Upper Rectal Cancer vol.260, pp.2, 2013, https://doi.org/10.1097/sla.0000000000000503
  2. Stereotactic/hypofractionated body radiation therapy as an effective treatment for lymph node metastases from colorectal cancer: an institutional retrospective analysis vol.90, pp.1079, 2013, https://doi.org/10.1259/bjr.20170422
  3. Mapping of lateral pelvic lymph node recurrences in rectal cancer: a radiation oncologist’s perspective vol.144, pp.6, 2018, https://doi.org/10.1007/s00432-018-2624-6